CorVista System with PH Add-On vs Imbio PHA (4.0.0)
AI Verdict
Choose CorVista System with PH Add-On if…
Choose CorVista System with PH Add-On if you require a rapid, non-invasive, point-of-care diagnostic solution for initial assessment of coronary artery disease and pulmonary hypertension. This tool is ideal when avoiding radiation, contrast agents, or extensive patient preparation is critical, providing quick results within minutes without the need for fasting or exercise.
View CorVista System with PH Add-On →Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA if you need automated, AI-powered analysis of cardiac structures from existing or planned CT pulmonary angiogram (CTPA) scans. This software is best suited for detailed assessment of right ventricular dilation and for aiding in the diagnosis and risk stratification of pulmonary embolism and hypertension, integrating directly into radiology workflows with annotated DICOM images and summary reports.
View Imbio PHA (4.0.0) →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | CorVista System with PH Add-On | Imbio PHA (4.0.0) |
|---|---|---|
| Deployment | Cloud-based, point-of-care system. | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). |
| FDA Status | 1 AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
CorVista System with PH Add-OnTool A, the CorVista System, offers a non-invasive, point-of-care diagnostic that requires no radiation, contrast agents, injections, fasting, or exercise, making it highly user-friendly for both patients and clinicians. In contrast, Tool B, Imbio PHA, relies on CT pulmonary angiogram (CTPA) scans, which are more invasive and resource-intensive, despite its efficient image processing.
Clinical Value
CorVista System with PH Add-OnBoth tools are FDA-cleared and provide significant clinical value. However, Tool A's non-invasive, point-of-care approach for rapid assessment of coronary artery disease and pulmonary hypertension introduces a novel diagnostic pathway that could enable earlier and less burdensome patient assessment, potentially reducing the need for more invasive procedures. Tool B enhances the analysis of existing imaging data, which is valuable but less transformative in its diagnostic approach.
Pricing & Value
TieBoth Tool A and Tool B state 'contact for pricing,' making it impossible to conduct a head-to-head comparison of their cost-effectiveness or overall value proposition. Without transparent pricing information, a definitive winner cannot be determined for this dimension.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA (Tool B) explicitly offers flexible deployment options, including cloud, enterprise (on-premise), or via partners, which caters to diverse IT infrastructures within healthcare organizations. Furthermore, its HIPAA compliance is 'third-party certified by compliancy group,' providing a stronger and more definitive assurance of enterprise-level regulatory adherence compared to Tool A's 'likely' status for HIPAA and BAA.
Innovation
CorVista System with PH Add-OnThe CorVista System (Tool A) represents a more disruptive innovation by offering a completely non-invasive, point-of-care diagnostic for complex cardiovascular conditions without traditional imaging or invasive procedures. While Imbio PHA (Tool B) innovates by automating and quantifying analysis from existing CTPA scans, Tool A's approach to data acquisition and diagnostic methodology is more fundamentally novel.
Support & Docs
Imbio PHA (4.0.0)Imbio PHA (Tool B) provides comprehensive and transparent support, including dedicated phone lines, email support, an online case submission portal, and 24/7/365 technical support, with user manuals available upon request. In contrast, public information for the CorVista System (Tool A) regarding dedicated customer support channels or publicly available documentation is considerably less detailed.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | CorVista System with PH Add-On | Imbio PHA (4.0.0) |
|---|---|---|
| Name | CorVista System with PH Add-On | Imbio PHA (4.0.0) |
| Primary Diagnostic Focus | rapid assessment of coronary artery disease and pulmonary hypertension | aid in the diagnosis and risk stratification of pulmonary embolism and hypertension (assessing potential right ventricular dilation from CTPA scans) |
| Input Data Type | cardiac and hemodynamic signals (non-invasive) | CT pulmonary angiogram (CTPA) scans |
| Key Output/Analysis | Machine-learned algorithms for analysis; analyzes cardiac and hemodynamic signals; secure web portal for physician access to analysis; modular design with disease-specific add-ons (CAD, PH). | Automated measurement of right and left ventricle diameters, main pulmonary artery and aorta diameters; calculates RV/LV and PA/Ao ratios; generates annotated DICOM images; provides summary reports in PDF format. |
| Radiation/Contrast Requirement | No radiation, contrast agents, injections, fasting, or exercise required. | Utilizes CT pulmonary angiogram (CTPA) scans. |
| Results Speed | Rapid results available within minutes. | Rapid, fully-automated assessment (typically in minutes). |
Videos
Demos, reviews, and walkthroughs featuring CorVista System with PH Add-On and Imbio PHA (4.0.0).